Innocrin Pharmaceuticals careers

Innocrin Pharmaceuticals Inc., a pharmaceutical company, discovers and develops oral inhibitors for the treatment of castration-resistant prostate cancer (CRPC). The company offers CYP17 lyase, a validated enzyme target for the treatment of CRPC and other hormonally-driven conditions, such as breast cancer, endometriosis, or congenital adrenal hyperlplasia. Its product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth–androgen biosynthesis and AR transcriptional signaling.